Clinical Trial

MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

Completed Phase 1
View on ClinicalTrials.gov →
Summary
This study will examine if at least one dose level of MK-4646 can lower HIV-1 viral load in a person's blood by a certain amount. The goals of this study are to learn about the safety of MK-4646 and if people tolerate it; and how HIV-1 viral load may decrease after starting to take MK-4646.
Protocol Amendment History 5 changes
critical Trial completed 2026-06-23
notable Enrollment reduced: 28 -> 15 participants 2026-06-23
notable Primary completion moved earlier: 2026-07-08 -> 2026-06-05 2026-06-23
minor Completion moved earlier: 2026-08-17 -> 2026-06-05 2026-06-23
minor Completion pushed: 2026-07-17 -> 2026-08-17 2026-05-27
Trial Details
NCT Number NCT07042945
Lead Sponsor Merck Sharp & Dohme LLC
Conditions HIV Infection
Enrollment 15 participants
Start Date 2025-07-09
Primary Completion 2026-06-05 (estimated)
Study Completion 2026-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-22